{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:25:46Z","timestamp":1792729546619,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82188102"],"award-info":[{"award-number":["82188102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472719"],"award-info":[{"award-number":["82472719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70001-5","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:34:22Z","timestamp":1771990462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-9617","authenticated-orcid":false,"given":"Yabing","family":"Nan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-637X","authenticated-orcid":false,"given":"Qingyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-7198","authenticated-orcid":false,"given":"Xiaowei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2415-1938","authenticated-orcid":false,"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuantong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-1177","authenticated-orcid":false,"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-3296","authenticated-orcid":false,"given":"Zhumei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-033X","authenticated-orcid":false,"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"70001_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"70001_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","volume":"33","author":"CL Scott","year":"2015","unstructured":"Scott, C. L., Swisher, E. M. & Kaufmann, S. H. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J. Clin. Oncol. 33, 1397\u20131406 (2015).","journal-title":"J. Clin. Oncol."},{"key":"70001_CR3","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980.e2975 (2018).","journal-title":"Cell Rep."},{"key":"70001_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 21, 1155\u20131164 (2020).","journal-title":"Lancet Oncol."},{"key":"70001_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726 (2020).","journal-title":"Nat. Commun."},{"key":"70001_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","volume":"5","author":"EK Lee","year":"2019","unstructured":"Lee, E. K. & Konstantinopoulos, P. A. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer 5, 524\u2013528 (2019).","journal-title":"Trends Cancer"},{"key":"70001_CR7","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1158\/1078-0432.CCR-16-2174","volume":"23","author":"A Afghahi","year":"2017","unstructured":"Afghahi, A. et al. Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance. Clin. Cancer Res. 23, 3365\u20133370 (2017).","journal-title":"Clin. Cancer Res."},{"key":"70001_CR8","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23, 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"70001_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1078-0432.CCR-13-0225","volume":"20","author":"P Bouwman","year":"2014","unstructured":"Bouwman, P. & Jonkers, J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 20, 540\u2013547 (2014).","journal-title":"Clin. Cancer Res."},{"key":"70001_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70001_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews, H. K., Bertoli, C. & de Bruin, R. A. M. Cell cycle control in cancer. Nat. Rev. Mol. Cell Biol. 23, 74\u201388 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70001_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78\u201394 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"70001_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"70001_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160\u20131166 (2007).","journal-title":"Science"},{"key":"70001_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616\u2013627 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70001_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73\u2013112 (2010).","journal-title":"Adv. Cancer Res."},{"key":"70001_CR17","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109\u20138115 (2006).","journal-title":"Cancer Res."},{"key":"70001_CR18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"70001_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).","journal-title":"Lancet Oncol."},{"key":"70001_CR20","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"70001_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984\u2013998 (2017).","journal-title":"Cancer Discov."},{"key":"70001_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge, E. J. et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat. Rev. Cancer 22, 102\u2013113 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"70001_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41587-020-0707-9","volume":"39","author":"L Cui","year":"2021","unstructured":"Cui, L. et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nat. Biotechnol. 39, 357\u2013367 (2021).","journal-title":"Nat. Biotechnol."},{"key":"70001_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-16-1326","volume":"23","author":"N Chan","year":"2017","unstructured":"Chan, N. et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin. Cancer Res. 23, 666\u2013676 (2017).","journal-title":"Clin. Cancer Res."},{"key":"70001_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17549-y","volume":"11","author":"L Aubert","year":"2020","unstructured":"Aubert, L. et al. Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer. Nat. Commun. 11, 3701 (2020).","journal-title":"Nat. Commun."},{"key":"70001_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41556-020-0481-4","volume":"22","author":"T Tsang","year":"2020","unstructured":"Tsang, T. et al. Copper is an essential regulator of the autophagic kinases ULK1\/2 to drive lung adenocarcinoma. Nat. Cell Biol. 22, 412\u2013424 (2020).","journal-title":"Nat. Cell Biol."},{"key":"70001_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature13180","volume":"509","author":"DC Brady","year":"2014","unstructured":"Brady, D. C. et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509, 492\u2013496 (2014).","journal-title":"Nature"},{"key":"70001_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov, P. et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat. Chem. Biol. 15, 681\u2013689 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"70001_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott, Z. et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194\u2013199 (2017).","journal-title":"Nature"},{"key":"70001_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","volume":"31","author":"SJ O\u2019Day","year":"2013","unstructured":"O\u2019Day, S. J. et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J. Clin. Oncol. 31, 1211\u20131218 (2013).","journal-title":"J. Clin. Oncol."},{"key":"70001_CR31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ccell.2025.03.031","volume":"43","author":"G Lei","year":"2025","unstructured":"Lei, G. et al. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer Cell43, 1076\u20131092.e5 (2025).","journal-title":"Cancer Cell"},{"key":"70001_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2025.02.015","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis. Cancer Cell 43, 937\u2013954.e9 (2025).","journal-title":"Cancer Cell"},{"key":"70001_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101928","volume":"42","author":"T Hong","year":"2021","unstructured":"Hong, T. et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 42, 101928 (2021).","journal-title":"Redox Biol."},{"key":"70001_CR34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/2159-8290.CD-23-1220","volume":"14","author":"G Lei","year":"2024","unstructured":"Lei, G. et al. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer Discov. 14, 1476\u20131495 (2024).","journal-title":"Cancer Discov."},{"key":"70001_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103350","volume":"76","author":"X Xie","year":"2024","unstructured":"Xie, X. et al. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors. Redox Biol. 76, 103350 (2024).","journal-title":"Redox Biol."},{"key":"70001_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84\u2013100.e108 (2023).","journal-title":"Cell Metab."},{"key":"70001_CR37","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov, P. et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375, 1254\u20131261 (2022).","journal-title":"Science"},{"key":"70001_CR38","doi-asserted-by":"publisher","first-page":"49599","DOI":"10.1074\/jbc.M408353200","volume":"279","author":"A Kumagai","year":"2004","unstructured":"Kumagai, A., Kim, S. M. & Dunphy, W. G. Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1. J. Biol. Chem. 279, 49599\u201349608 (2004).","journal-title":"J. Biol. Chem."},{"key":"70001_CR39","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.1217781110","volume":"110","author":"S Liu","year":"2013","unstructured":"Liu, S., Ho, C. K., Ouyang, J. & Zou, L. Nek1 kinase associates with ATR-ATRIP and primes ATR for efficient DNA damage signaling. Proc. Natl. Acad. Sci. USA 110, 2175\u20132180 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70001_CR40","doi-asserted-by":"crossref","unstructured":"Biller, M. et al. REV7 associates with ATRIP and inhibits ATR kinase activity. Nucleic Acids Res. 54, gkaf1527 (2026).","DOI":"10.1093\/nar\/gkaf1527"},{"key":"70001_CR41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/science.1065521","volume":"294","author":"D Cortez","year":"2001","unstructured":"Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling. Science 294, 1713\u20131716 (2001).","journal-title":"Science"},{"key":"70001_CR42","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1091\/mbc.e04-11-1006","volume":"16","author":"HL Ball","year":"2005","unstructured":"Ball, H. L., Myers, J. S. & Cortez, D. ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation. Mol. Biol. Cell 16, 2372\u20132381 (2005).","journal-title":"Mol. Biol. Cell"},{"key":"70001_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ccell.2022.07.012","volume":"40","author":"S Pal","year":"2022","unstructured":"Pal, S. et al. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell 40, 957\u2013972.e910 (2022).","journal-title":"Cancer Cell"},{"key":"70001_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","volume":"40","author":"DD Shi","year":"2022","unstructured":"Shi, D. D. et al. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell 40, 939\u2013956.e916 (2022).","journal-title":"Cancer Cell"},{"key":"70001_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s42255-023-00735-9","volume":"5","author":"J Shin","year":"2023","unstructured":"Shin, J. et al. Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle. Nat. Metab. 5, 277\u2013293 (2023).","journal-title":"Nat. Metab."},{"key":"70001_CR46","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/s42255-024-01166-w","volume":"6","author":"M Nam","year":"2024","unstructured":"Nam, M. et al. Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition. Nat. Metab. 6, 2338\u20132353 (2024).","journal-title":"Nat. Metab."},{"key":"70001_CR47","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","volume":"33","author":"S Christian","year":"2019","unstructured":"Christian, S. et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 33, 2403\u20132415 (2019).","journal-title":"Leukemia"},{"key":"70001_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16544-7","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat. Commun. 11, 2788 (2020).","journal-title":"Nat. Commun."},{"key":"70001_CR49","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41557-022-00984-3","volume":"14","author":"J Han","year":"2022","unstructured":"Han, J. et al. Conformational and functional changes of the native neuropeptide somatostatin occur in the presence of copper and amyloid-\u03b2. Nat. Chem. 14, 1021\u20131030 (2022).","journal-title":"Nat. Chem."},{"key":"70001_CR50","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","volume":"25","author":"K Parmar","year":"2019","unstructured":"Parmar, K. et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition. Clin. Cancer Res. 25, 6127\u20136140 (2019).","journal-title":"Clin. Cancer Res"},{"key":"70001_CR51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 (2019).","journal-title":"Cancer Discov."},{"key":"70001_CR52","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-18-2480","volume":"79","author":"LA Young","year":"2019","unstructured":"Young, L. A. et al. Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress. Cancer Res. 79, 3762\u20133775 (2019).","journal-title":"Cancer Res."},{"key":"70001_CR53","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","volume":"82","author":"Z Wilson","year":"2022","unstructured":"Wilson, Z. et al. ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res. 82, 1140\u20131152 (2022).","journal-title":"Cancer Res."},{"key":"70001_CR54","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah, P. D. et al. Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 163, 246\u2013253 (2021).","journal-title":"Gynecol. Oncol."},{"key":"70001_CR55","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso, G., Weroha, S. J. & Cliby, W. Ovarian cancer: a review. JAMA 334, 1278\u20131291 (2025).","journal-title":"JAMA"},{"key":"70001_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen, N. J. & Singh, P. K. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat. Rev. Cancer 23, 275\u2013294 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"70001_CR57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown, K. K., Spinelli, J. B., Asara, J. M. & Toker, A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 7, 391\u2013399 (2017).","journal-title":"Cancer Discov."},{"key":"70001_CR58","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1158\/2767-9764.CRC-23-0370","volume":"4","author":"M Poliakova Turan","year":"2024","unstructured":"Poliakova Turan, M. et al. E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer Res. Commun. 4, 1863\u20131880 (2024).","journal-title":"Cancer Res. Commun."},{"key":"70001_CR59","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger, K. et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 372, 156\u2013165 (2021).","journal-title":"Science"},{"key":"70001_CR60","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/0008-5472.CAN-25-0043","volume":"86","author":"H Cardenas","year":"2025","unstructured":"Cardenas, H. et al. Metabolic dependency on de novo pyrimidine synthesis is a targetable vulnerability in platinum resistant ovarian cancer. Cancer Res. 86, 387\u2013401 (2025).","journal-title":"Cancer Res."},{"key":"70001_CR61","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"70001_CR62","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","volume":"185","author":"H Kalkavan","year":"2022","unstructured":"Kalkavan, H. et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell 185, 3356\u20133374.e3322 (2022).","journal-title":"Cell"},{"key":"70001_CR63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"70001_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30568-1","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).","journal-title":"Nat. Commun."},{"key":"70001_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101264","volume":"4","author":"T Xing","year":"2023","unstructured":"Xing, T. et al. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. Cell Rep. Med. 4, 101264 (2023).","journal-title":"Cell Rep. Med."},{"key":"70001_CR66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.molcel.2024.11.013","volume":"85","author":"Q Liao","year":"2025","unstructured":"Liao, Q. et al. p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis. Mol. Cell 85, 132\u2013149.e137 (2025).","journal-title":"Mol. Cell"},{"key":"70001_CR67","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ymthe.2022.10.006","volume":"31","author":"Y Nan","year":"2023","unstructured":"Nan, Y. et al. HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity. Mol. Ther. 31, 552\u2013568 (2023).","journal-title":"Mol. Ther."},{"key":"70001_CR68","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"70001_CR69","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1158\/0008-5472.CAN-22-0717","volume":"82","author":"Y Nan","year":"2022","unstructured":"Nan, Y. et al. DLGAP1-AS2-mediated phosphatidic acid synthesis activates YAP signaling and confers chemoresistance in squamous cell carcinoma. Cancer Res. 82, 2887\u20132903 (2022).","journal-title":"Cancer Res."},{"key":"70001_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315348121","volume":"121","author":"Y Nan","year":"2024","unstructured":"Nan, Y. et al. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. Proc. Natl. Acad. Sci. USA 121, e2315348121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70001-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:03:08Z","timestamp":1775088188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70001"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70001-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3142"}}